27-amino acid mammalian counterpart, gastrin-releasing peptide (GRP), are considered as generalized "onswitches" in the gastrointestinal tract with actions that include stimulation of peptide release, gastric and pancreatic secretion, and gut motility (8, 25, 35) . GRP acts through its specific receptor, the GRP-receptor (GRP-R), which belongs to the G protein-coupled receptor superfamily (4, 39, 53) , and is located throughout the gut and pancreas (8, 14, 19, 32) . In addition to its effects on secretion and motility, GRP acts as a potent mitogen for certain normal and neoplastic tissues. This mitogenic effect was first reported in human small cell lung cancers that express the GRP-R and secrete GRP, thus suggesting an autocrine mechanism of action for GRP in these tumors (12) . In addition, high-affinity GRP-R has been identified in gastrointestinal tract cancers such as pancreatic, gastric, and colonic adenocarcinomas (6, 8, 14, 21, 26, 43, 45, 46, 54, 55) . Thus GRP acts as a potent mitogen for certain human gut and pancreatic cancers. The signal transduction pathways responsible for the multiple cellular effects of BBS remain to be clearly defined in the mammalian system.
BBS was initially thought to act as a mitogen in Swiss 3T3 fibroblasts through the activation of phospholipase C (PLC), which catalyzes hydrolysis of phosphatidylinositol 4,5-bisphosphate and produces inositol 1,4,5-trisphosphate (IP 3 ) and 1,2-diacylglycerol (DAG; see Ref. 48) . IP 3 stimulates the release of Ca 2ϩ from intracellular stores, and DAG activates protein kinase C (PKC; see Ref. 39) . Both the PKC pathway and PLC-independent Ca 2ϩ -mobilizing pathway (Ca 2ϩ -calmodulin pathway) are known to stimulate cell growth (48) . BBS also increases cAMP production, which is known to stimulate the growth of certain cells. Evidence to support the importance of BBS-mediated induction of cAMP is provided by the report of Benya et al. (5) showing that the inhibition of BBS activation of protein kinase A (PKA) in Swiss 3T3 cells inhibits cell proliferation. Furthermore, other reports have postulated that the mitogenic action of BBS is mediated through activation of nonreceptor protein tyrosine kinases (PTKs; see Refs. 56 and 57) . The inhibitor of PTK, tyrphostin, inhibits BBS-stimulated growth of Swiss 3T3 cells (52) , thus supporting this hypothesis. From these studies, it appears that GRP and BBS act through multiple, cell-specific signal transduction pathways to regulate cell proliferation (49) . These signaling pathways converge upon specific transcription factors, which bind to target genes and ultimately regulate cellular growth.
The large family of activator protein-1 (AP-1) transcription factors, constituted by members of the jun (c-Jun, JunB, JunD) and fos gene families, binds to the phorbol ester-responsive enhancer (TGAGTCA) located in certain genes as either homo-or heterodimers (9, 11, 49) . Both jun and fos were originally recognized as viral oncogenes, and their cellular counterparts are the "immediate early genes" that are induced by a wide variety of mitogens, including BBS (16, 37) ; the immediate early genes also mediate proliferation in certain cell types (2, 29) . Previously, we have shown that the human gastric adenocarcinoma SIIA, which was established in our laboratory (3), possesses a native GRP-R that binds BBS with high affinity (6); treatment of SIIA cells with BBS results in increased intracellular Ca 2ϩ mobilization and induction of AP-1 gene and protein expression and DNA binding activity (31) .
The signaling mechanisms responsible for BBS-mediated AP-1 activation in SIIA cells are not known. Therefore, the purpose of our present study was to determine whether AP-1 activation occurs as a result of PKC, PKA, and/or PTK stimulation in SIIA cells. Delineation of these mechanisms will provide a better understanding of BBS-mediated AP-1 gene activation in gastric cancers and may have potential implications in the adjuvant treatment of some of these neoplasms.
MATERIALS AND METHODS

Materials.
Restriction, ligation, and other DNA-modifying enzymes were purchased from Promega (Madison, WI) or Stratagene (La Jolla, CA). Nylon membranes (Zetaprobe) were from Bio-Rad Laboratories (Hercules, CA), and oligo(dT)-cellulose (type III) was purchased from Collaborative Biomedical Products (Bedford, MA). Nucleotides and poly(dI ⅐ dC) were purchased from Pharmacia LKB Biotechnology (Piscataway, NJ), and radioactive compounds were obtained from NEN (Wilmington, DE). The GRP-R antagonists BIM-26226 and [D-Tyr 6 ]Bn-(6O13) methyl ester (ME) were from Biomeasure (Milford, MA) and Dr. Robert Jensen (National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD), respectively. Protein kinase inhibitors (H-7, H-8, and H-89), and the tyrosine kinase inhibitor (tyrphostin-25 and its control tyrphostin-1) were obtained from Biomol (Plymouth Meeting, PA). The phorbol ester phorbol 12-myristate 13-acetate (PMA), the cAMP agonist forskolin (FSK), and actinomycin D were obtained from Sigma (St. Louis, MO). The AP-1 cDNA probes and ␤-actin were obtained from American Type Culture Collection (Rockville, MD) and were labeled using a random primer kit (Random Prime-it II) from Stratagene. The phosphorylated c-Jun antibody (KM-1) and the antibody to c-Fos (4-10G) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). The enhanced chemiluminescence (ECL) system for Western immunoblot analysis was from Amersham (Arlington Heights, IL). The oligonucleotide containing consensus AP-1 binding sites was from Promega. Tissue culture media and reagents were obtained from GIBCO BRL (Grand Island, NY). All other reagents were of molecular biology grade and were obtained from either Sigma or Amresco (Solon, OH).
Tissue culture. The human gastric cancer cell line SIIA was established and characterized in our laboratory (3) . SIIA cells (passages [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] were maintained in F-10 media with 10% FCS in a humidified atmosphere of 95% air and 5% CO 2 at 37°C.
RNA extraction and Northern blot analysis. Cells were harvested, and RNA was extracted by the method of Schwab et al. (51) . Polyadenylated [Poly(A) ϩ ] RNA was selected from all samples using oligo(dT)-cellulose, electrophoresed in 1.2% agarose-formaldehyde gels, transferred to nylon membranes, and hybridized with the cDNA probes. Hybridization and washing conditions were described previously (18, 31) . Blots were stripped and reprobed with the constitutively expressed ␤-actin gene to ensure intact RNA samples and equality of loading.
Protein extraction and Western immunoblot analysis. Nuclear and cytoplasmic protein was extracted from SIIA cells as described by Schreiber et al. (50) ; concentrations were measured using the method of Bradford (7) . Protein lysates were resolved by 10% SDS-PAGE and electroblotted to nitrocellulose membranes as described previously (18, 31) . Membranes were blocked overnight in 5% milk with 0.05% Tween 20 in Tris-buffered saline solution and were incubated for 3 h with either an antibody that recognizes phosphorylated c-Jun (1:500) or an antibody to c-Fos (1:1,000). Filters were washed and then incubated with a horseradish peroxidaseconjugated goat anti-rabbit IgG as a secondary antibody (1:500 dilution) for 1 h. The blots were developed using ECL detection.
Preparation of nuclear extracts and electrophoretic mobility shift assays. Crude nuclear extracts were prepared from SIIA cells according to the method described by Schreiber et al. (50) . The extracts were quick-frozen, stored in aliquots at Ϫ80°C, and used within 2 mo of extraction.
Electrophoretic mobility shift assays (EMSAs) were performed as described previously (17, 31) . Briefly, the AP-1 oligonucleotide was labeled with [␥-32 P]ATP and T4 polynucleotide kinase. EMSA mixtures contained 30-50,000 counts/ min (ϳ0.5 ng) of 32 P end-labeled oligonucleotide and 10-20 g of nuclear protein in a final volume of 20 l of 12.5 mM HEPES (pH 7.9), 100 mM KCl, 10% glycerol, 0.1 mM EDTA, 0.75 mM dithiothreitol, 0.2 mM phenylmethylsulfonyl fluoride, and 1 g of poly(dI ⅐ dC) as a nonspecific competitor. The reaction was incubated for 20 min at room temperature. Competition binding experiments were performed by first incubating the competitor fragment, in molar excess, with the nuclear protein extract and binding buffer for 10 min on ice. The labeled probe was then added and incubation continued for 15 min at room temperature. The reaction mixtures were loaded on a 6% nondenaturing polyacrylamide gel and were resolved by electrophoresis at 200 V for 2-3 h. The gels were subsequently dried, and autoradiography was performed.
jun-B, their corresponding proteins, and AP-1 binding activity in the human gastric cancer cell line SIIA (31) . The increases noted in mRNA expression occur early, suggesting that BBS is acting through its receptor to activate AP-1 gene transcription in SIIA cells.
To confirm these assumptions, we first determined the effect of pretreatment with two different GRP-R antagonists (15, 38) , BIM-26226 and ME, on BBSmediated induction of c-jun, jun-B, c-fos, and jun-D mRNAs. Treatment with BBS (20 nM) produced a rapid induction of both c-jun and jun-B mRNA levels by 30 min (3-and 2.8-fold induction, respectively) with maximal levels achieved by 1 h after treatment (5-and 3-fold induction compared with control levels, respectively; Fig. 1A ). Pretreatment for 2 h with either BIM-26226 (100 nM) or ME (10 nM) and harvesting the RNA 1 h after the addition of BBS demonstrated that both agents effectively blocked BBS-mediated induction of c-jun and jun-B (Fig. 1A , lanes 7 and 9) compared with cells treated with BBS and the vehicle (i.e., 0.05% DMSO) used to dissolve the BIM-26226 compound (Fig. 1A, lane 5) . These antagonists had no effect on the levels of c-jun and jun-B when given alone (lanes 6 and 8). Expression of c-fos, which is constitutively elevated in SIIA, was only minimally increased at 30 min and 1 h after BBS addition (ϳ1.5-fold compared with control). Both BIM-26226 and ME blocked this minimal induction of c-fos mRNA. In addition, we elevated the effect of BBS on jun-D expression and found, similar to c-fos, high basal levels of jun-D in untreated SIIA cells, with only a minimal induction noted with addition of BBS (data not shown). The blot was stripped and reprobed with ␤-actin to confirm intact RNA and relative equality of loading. Collectively, these findings confirm our previous results of a rapid induction of both c-jun and jun-B after BBS treatment (31) . Both of the specific GRP-R antagonists effectively blocked the induction of AP-1 gene expression, demonstrating a direct receptor-mediated effect by BBS.
We next performed Western blot analyses using cytoplasmic and nuclear protein extracts to confirm that treatment with BBS stimulates AP-1 protein expression (Fig. 1B) . Previously, we have shown that BBS stimulates steady-state protein levels of c-Jun and JunB (31) . Using an antibody specific to phosphorylated (i.e., active) c-Jun, we demonstrate a dramatic induction of phosphorylated c-Jun expression at 30 min after treatment (lane 6); this induction was maintained for the duration of the time course (i.e., 4 h). Similar to c-fos mRNA, c-Fos protein levels are increased basally in untreated SIIA cells (lane 5); treatment with BBS resulted in an increase of c-Fos levels compared with control (lanes 6-8). As expected, the expression of c-Jun and c-Fos was limited to the nuclear fractions. Therefore, our Western blot results showing an increase in phosphorylated c-Jun and in c-Fos protein levels correlates with our findings of BBS-mediated AP-1 mRNA induction by BBS.
Inhibition of BBS-mediated AP-1 activation by actinomycin D suggests regulation at the transcriptional level.
The rapid induction (within 30 min) of c-jun and jun-B suggested that BBS regulates AP-1 activation at the transcriptional level. To better ascertain whether regulation was due to an increase in transcription, actinomycin D (5 g/ml), which inhibits RNA synthesis (40) , was added to SIIA cells at the time of BBS treatment, and cells were harvested 1 h later (Fig. 2) . Actinomycin D effectively blocked BBS-mediated AP-1 induction (lane 5) compared with BBS treatment alone (lane 2) or BBS combined with the vehicle (i.e., 0.01% methanol) used to dilute the actinomycin D (lane 3). Also, addition of actinomycin D alone had no effect on c-jun or jun-B expression (lane 4) compared with control (untreated) cells (lane 1). These findings, in combination with the rapid induction of these AP-1 genes, provide evidence to suggest that BBS regulates the transcription of these genes in SIIA cells. Fig. 3A) . The phorbol ester PMA activates both conventional and novel PKC isozymes (42) , whereas the diterpene FSK activates the PKA-dependent pathways directly through adenylyl cyclase/cAMP (34) . For the remainder of our studies, we have focused on c-jun and jun-B, since BBS had only minimal effects on c-fos and jun-D mRNA levels in SIIA cells.
As expected, treatment of SIIA cells with BBS increased the expression of c-jun and jun-B at 1 h after treatment (Fig. 3A, lane 3 . Similar to the time course experiment with BBS, the induction of these immediate early genes was transient with return to baseline levels at 6 h (lane 6). The increase in c-jun expression with PMA was comparable to that with BBS; however, jun-B expression was increased more with addition of PMA than with BBS. Treatment with FSK had minimal to no effect on the expression of c-jun (Fig. 3A, lanes 7-9) . In contrast, jun-B levels were increased 3.8-fold at 1 h after FSK treatment compared with control; this increase was not as pronounced as with PMA.
To determine whether the PMA-mediated stimulation of AP-1 gene expression correlated with increases in AP-1 binding activity, EMSAs were performed using a labeled oligonucleotide probe containing the consensus AP-1 binding site (Fig. 3B) 
PKC inhibitors block BBS-mediated AP-1 activation.
To further delineate the role of PKC and PKA pathways in BBS-mediated induction of AP-1 expression, various protein kinase inhibitors were added before the addition of BBS. SIIA cells were pretreated for 2 h with the protein kinase inhibitors H-7, H-8, or H-89 (25 M each), and then BBS (10 nM) was added for an additional 1 h (Fig. 4A) . Both H-7 and H-8 are primarily PKC inhibitors (28) , whereas H-89 is a selective PKA inhibitor (10) . BBS treatment resulted in increased expression of both c-jun and jun-B at 1 h (lane 2); pretreatment with the vehicle (i.e., 0.01% ethanol) used to dissolve H-7, H-8, and H-89 did not affect BBS-mediated c-jun and jun-B induction (lane 3). Pretreatment of SIIA cells with either H-7 or H-8 (lanes 4 and 5, respectively) inhibited the BBS-mediated induction of both c-jun and jun-B, with the H-7 compound more effective. In contrast, pretreatment with H-89 had little effect on the AP-1 induction by BBS (lane 6).
As control experiments, the effects of H-7 and H-89 on basal (lanes 1-3) and PMA-stimulated (lanes 4-6) expression of c-jun and jun-B were assessed (Fig. 4B) . Basal levels of both c-jun and jun-B were decreased by pretreatment with H-7, suggesting that the PKC pathway plays a role in constitutive AP-1 gene expression (lane 2). The PKA-inhibitor H-89 had no effect on basal jun-B expression but, surprisingly, resulted in an increase of c-jun expression, suggesting that PKA may actually suppress basal c-jun expression in SIIA cells To determine whether H-7 and H-8 can also inhibit the increase in AP-1 binding activity, EMSAs were performed using a labeled AP-1 oligonucleotide added to SIIA nuclear extracts ( Collectively, these studies demonstrate that the PKC intracellular pathway plays an integral role in BBSmediated AP-1 activation in the SIIA cell line.
Attenuation of BBS-mediated AP-1 induction by tyrphostin-25.
In addition to activation of PKC, BBS can activate nonreceptor PTKs in certain cells (8, 41, 56) ; tyrphostin, an inhibitor of these kinases, can block BBS-mediated growth of Swiss 3T3 cells (52) . Therefore, we next determined whether BBS could affect AP-1 induction in SIIA cells through a PTK pathway (Fig. 6) . As demonstrated previously, BBS treatment stimulated c-jun and jun-B mRNA levels at 1 h (lane 2); pretreatment with 1 M of the PTK inhibitor tyrphostin-25 (22, 23) attenuated the induction of both c-jun and jun-B (lane 5). In contrast, pretreatment with either the vehicle (i.e., 0.05% DMSO) or tyrphostin-1 (a negative control for tyrphostin-25) did not affect AP-1 induction after BBS treatment (lanes 3 and 4, respectively). Taken together, our results demonstrate involvement of both the PKC-and the PTK-dependent pathways in the induction of the AP-1 genes c-jun and jun-B in response to BBS. Conversely, PKA-dependent pathways do not appear to play a significant role in AP-1 induction in SIIA cells.
DISCUSSION
Previously, we identified the high-affinity GRP-R in the human gastric cancer SIIA (6) . BBS stimulates Ca 2ϩ mobilization and AP-1 gene induction in SIIA cells (31) . In our present study, we have confirmed the induction of various AP-1 genes after addition of BBS, noting that this induction was both rapid (within 30 min) and transient (ending in 4 h). Specifically, we found that the induction of c-jun and jun-B was more pronounced than either c-fos or jun-D, which are both expressed at high levels in untreated SIIA cells. Pretreatment with the specific GRP-R antagonists BIM-26226 and ME effectively blocked the BBS-mediated AP-1 gene induction, further confirming that BBS is acting directly through its high-affinity receptor to stimulate AP-1 gene expression in SIIA cells. Furthermore, we demonstrate that the BBS-mediated induction of c-jun and jun-B in SIIA cells likely occurs as a result of increased gene transcription.
Depending on the cell type and the particular mitogen, the induction of the AP-1 genes can occur by a variety of signaling mechanisms, including both PKCand PKA-dependent pathways (29, 30) . The activation of c-jun is thought to be primarily through a PKCdependent pathway, since treatment of various cells with phorbol ester rapidly induces transcription of the c-jun gene (27) . In contrast, jun-B can be activated through both PKC-and PKA-dependent pathways (13, 30) . We assessed whether these pathways contribute to (which primarily inhibit PKC-dependent pathways; see Ref. 28) , or H-89 (which is a predominant inhibitor of PKA; see Ref. 10 ). Our results demonstrate that addition of either H-7 or H-8 inhibited the induction of c-jun and jun-B. On the other hand, H-89 had little effect on the BBS-mediated induction. These findings demonstrate the involvement of PKC-dependent signaling pathways in BBS-mediated AP-1 induction of SIIA cells, whereas PKA does not appear to play a significant role in this response.
In addition to the stimulation of PKC-dependent pathways by BBS, other studies indicate that the GRP-R is coupled to nonreceptor PTK activation in certain cell types. For example, BBS stimulates expression of the immediate early genes c-myc and c-fos through a PTK-mediated pathway in Swiss 3T3 cells (35) . In addition, a recent report by Nishino et al. (41) demonstrated that BBS acts through three different signaling pathways, including PTK, in rat pancreatic acini to affect secretion. Therefore, we next determined whether PTK pathways contribute to the AP-1 gene induction noted with BBS treatment in SIIA cells. Addition of tyrphostin-25, a potent general PTK inhibitor (22, 23, 41) , to SIIA cells before BBS treatment markedly attenuated c-jun and jun-B induction, whereas treatment with tyrphostin-1, a negative control for tyrphostin-25, had no effect on the BBS-mediated response. These findings provide compelling evidence that both PKC-and PTK-dependent pathways are involved in the BBS-mediated induction of c-jun and jun-B in the SIIA cell line. Consistent with our findings using BBS, others have shown that stimulation of both PKC-and PTK-dependent pathways is required for optimal AP-1 induction in both myogenic cells and the Jurkat T cell line in response to reactive oxygen intermediates (36, 44) . In fact, depending on the extracellular stimulus, PTK activation may be the predominant mechanism leading to AP-1 induction, as noted by the stimulation of c-jun expression with arachidonic acid treatment in stromal cells (47) .
Although not as common in the United States, gastric cancer is estimated to be one of the more common cancers worldwide, with an increased incidence in certain endemic areas such as Japan, Eastern Europe, and South America (33) . Therapeutic options are limited, since radiation and chemotherapy are, for the most part, ineffective in increasing survival in patients with metastatic disease; the cellular mechanisms regulating gastric cancer growth remain unknown. Previously, we have identified expression of GRP-R in two gastric cancer cell lines (SIIA and MKN45) and in three of five human gastric cancer xenografts (31) . Consistent with our findings, Preston et al. (43) demonstrated that 13 of 23 gastric cancers expressed highaffinity GRP-R. The presence of GRP-R in gastric cancers appears to play a functional role in the growth of these tumors, as noted by Qin et al. (45) who demonstrated that the GRP antagonist RC-3095 blocks the growth of the human gastric cancer Hs 746T both in vitro and when placed as xenografts in nude mice. Recently, Ferris et al. (20) reported that the constitutive activation of GRP-R in nonmalignant colonic epithelial cells results in cellular proliferation, suggesting a role for GRP-R as a potential oncogene in certain cancers; therefore, it is interesting to speculate whether the expression of GRP-R in SIIA cells contributes to the high basal expression of the c-fos and jun-D genes noted in our study. We suspect that the induction of AP-1 proteins may play a role in the mitogenic effect of GRP in certain gut neoplasms, since the activation of these transcription factors is important for the mitogen-induced growth of other tumors (2, 29) . Our future studies may address which specific PKC isozymes and nonreceptor PTKs mediate agonist-stimulated AP-1 activation in SIIA cells. Furthermore, we will assess the effects of blocking specific AP-1 genes or second messenger pathways (e.g., PKC or PTK; see Ref. 24 ) on the growth regulation of GRP-R-expressing gastric cancers.
In conclusion, we have confirmed the rapid induction of AP-1 gene expression and DNA binding in the SIIA gastric cancer cell line in response to BBS. This induction of AP-1 genes was selective, with a more pronounced effect noted on the expression levels of c-jun and jun-B; both c-fos and jun-D were constitutively expressed in SIIA cells and were only minimally affected by BBS. The induction of AP-1 is mediated through the high-affinity GRP-R and appears to be due to an increase in gene transcription. Finally, using various protein kinase inhibitors, we have established that the BBS-induced increase in c-jun and jun-B expression involves both PKC-and PTK-dependent signaling pathways, with the PKA pathway appearing not to play a significant role. Delineation of the intracellular signaling pathways may provide the cellular basis for improved adjuvant agents to target specific cellular pathways in gastric cancers.
